Aptus Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Aptus Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.02M	Buy	21,335 +4,502	+27%	+$197K	0.01%	580
2025 Q4	$650K	Buy	16,833 +2,750	+20%	+$105K	﹤0.01%	674
2025 Q3	$497K	Buy	14,083 +3,369	+31%	+$122K	﹤0.01%	700
2025 Q2	$386K	Buy	+10,714	New	+$355K	﹤0.01%	745

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aptus Capital Advisors's RPRX Position: Q1 2026 in Review

Aptus Capital Advisors increased its Royalty Pharma (RPRX) stake by 27% in Q1 2026, buying an estimated $197K and bringing the position to 21,335 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #580.

Aptus Capital Advisors first reported a position in RPRX in Q2 2025 and has held it in 4 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Aptus Capital Advisors held 21,335 shares of Royalty Pharma worth $1.02M as of Q1 2026.
Aptus Capital Advisors bought 4,502 Royalty Pharma shares in Q1 2026, an estimated $197K.
Royalty Pharma made up 0.01% of Aptus Capital Advisors's portfolio in Q1 2026, its #580 holding.
Aptus Capital Advisors first reported a position in Royalty Pharma in Q2 2025 and has held it in 4 quarters since.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.